Breast Cancer Clinical Trial
— ExciteOfficial title:
Exercise Intensity Trial (EXCITE): A Randomized Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer
NCT number | NCT01186367 |
Other study ID # | 15-147 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 11, 2010 |
Est. completion date | May 17, 2023 |
Verified date | March 2024 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the effects of 3 different approaches to exercise training in women with early stage breast cancer who have completed all primary treatments (except hormone therapy, if appropriate). Prior research in women with early stage breast cancer has shown that some treatments may have an adverse impact on physical fitness levels leading to feelings of fatigue and poor quality of life. Supervised exercise training has been shown to reduce some of these side-effects. However, all the exercise programs have followed essentially the same approach. This study is designed to see if a different approach to exercise training is more effective than the conventional approach currently in use.
Status | Completed |
Enrollment | 174 |
Est. completion date | May 17, 2023 |
Est. primary completion date | May 17, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 21 Years to 80 Years |
Eligibility | Inclusion Criteria: - Aged 45-80 years - Female - Has been diagnosed with early-stage breast cancer - Post-menopausal, defined as : - Age = 45 with no menses for at least 2 years - Chemically induced menopause through ovarian suppression, as determined by the primary oncologist - An interval of at least one year, but no more than five years, following the full completion of primary therapy for malignant disease. Primary therapy is defined as: - Surgery plus radiation - Surgery plus chemotherapy - Surgery plus trastuzumab - Surgery plus hormone therapy Note: For patients who receive hormone therapy following surgery, the definition of one-year post-completion of therapy is defined by the surgery date. Patients who are currently receiving hormone therapy are eligible for enrollment. - Weight of < 205 kgs - ECOG status of 0 or 1 - Life expectancy = 6 months - Performing less than 150 minutes of structured moderate-intensity or strenuous intensity exercise per week. - Exercise intolerance defined by a VO2peak below that predicted for sedentary age and sex-matched individuals as defined in Appendix H. - Willing to be randomized to one of the study arms - Able to complete an acceptable baseline CPET, in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the investigator. - Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria: - Achieving a plateau in oxygen consumption, concurrent with an increase in power output; - A respiratory exchange ratio = 1.10; - Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]); - Volitional exhaustion, as measured by a rating of perceived exertion (RPE) = 18 on the BORG scale. Exclusion Criteria: - Any of the following absolute contraindications to cardiopulmonary exercise testing: - Acute myocardial infarction within 3-5 days of any planned study procedures; - Unstable angina; - Uncontrolled arrhythmia causing symptoms or hemodynamic compromise; - Recurrent syncope; - Active endocarditis; - Acute myocarditis or pericarditis; - Symptomatic severe aortic stenosis; - Uncontrolled heart failure; - Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures - Thrombosis of lower extremities; - Suspected dissecting aneurysm; - Uncontrolled asthma; - Pulmonary edema; - Respiratory failure; - Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis); - Presence of any other concurrent, actively treated malignancy - History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer) - Presence of metastatic disease - Room air desaturation at rest = 85% - Mental impairment leading to inability to cooperate - Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Duke University |
United States,
Scott JM, Thomas SM, Peppercorn JM, Herndon JE 2nd, Douglas PS, Khouri MG, Dang CT, Yu AF, Catalina D, Ciolino C, Capaci C, Michalski MG, Eves ND, Jones LW. Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To compare the effect of high-intensity to moderate-intensity aerobic training, relative to attention-control, on peak oxygen consumption. | VO2 or peak oxygen consumption will be measured at 3 time-points. Baseline, mid-point (8 weeks), and post-intervention (16 weeks). | 3 time-points |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |